The Valley Hospital is a 451-bed, acute-care, not-for-profit hospital in Ridgewood, Bergen County, New Jersey. Valley staff includes more than 1,100 physicians, 3,700 employees and 3,000 volunteers.In 2020, Valley recorded 41,345 admissions, 51,792 emergency department visits and 3,528 births.The Valley Hospital is part of Valley Health System, which also includes Valley Home Care and Valley Medical Group..
BACKGROUND:With catheter-based interventions increasingly requiring large-bore venous access, reliable closure methods for 16-17F sheaths are essential. Current manual compression techniques can prolong recovery, delay ambulation and discharge candidacy, and cause patient discomfort. The VASCADE MVP XL Venous Vascular Closure System is designed to address this gap. OBJECTIVE:The AMBULATE EXPAND trial was a prospective, single-arm, multi-center pivotal study designed to evaluate the safety and efficacy of the investigational device for closure of large-bore femoral venous access sites, and to generate evidence for customary regulatory review. METHODS:This trial (February-September of 2025) enrolled patients undergoing non-emergent procedures requiring a single 16-17F outer diameter (OD) sheath and optional smaller sheaths. The primary efficacy endpoint was time to ambulation. The primary safety endpoint was the 30-day rate of major access-site complications. Secondary endpoints included time to hemostasis, total post-procedure time, discharge eligibility, device success, and 30-day rate of minor access-site complications. RESULTS:A total of 77 patients were enrolled with none lost to follow-up. The study met both primary efficacy and safety endpoints. The mean time to ambulation was 3.2 h, and mean time to hemostasis was 2.7 min. The mean total post-procedure and time to discharge eligibility were 3.3 and 3.4 h, respectively. Device success was achieved in 98.7% of access sites. The primary safety endpoint of major venous access site closure-related complications over 30 days was 0%. Minor venous access site closure-related complications were also 0%. CONCLUSIONS:The study results demonstrate that the VASCADE MVP XL device provides safe and effective percutaneous closure of femoral venous access sites after catheter-based procedures using 16-17F OD sheaths. Compared to standard performance goals from manual compression, the VASCADE MVP XL significantly reduced time to ambulation, hemostasis, discharge eligibility, and overall post-procedure time.
Although cardiovascular disease (CVD) is the leading cause of mortality in women, CVD in women has long been understudied and underdiagnosed. This is largely based on a misconception that hearts in women are similar to those in men with regard to physiological characteristics and physiological responses. Nonetheless, in an era characterized by rapid advances in diagnostic cardiac imaging modalities, there is a greater need to understand sex differences in cardiac anatomy and function, and how these might influence CVD patterns. Such differences include observations that women have greater left ventricular (LV) ejection fraction and more pronounced LV hypertrophy compared with men using echocardiography and magnetic resonance imaging (MRI) respectively. Imaging can help reveal microvascular dysfunction and heart failure, both of which have different characteristics in women compared with men. This review aims to provide a brief summary of the sex differences in cardiovascular pathophysiology among men and women observed across various imaging modalities, including echocardiography, MRI, coronary computed tomography angiography, positron emission tomography, and stress testing, while also referencing sex differences in electrophysiology with respect to cardiac anatomy.